Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma

Adam S. Sperling, Benjamin A. Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Nina Orwitz, David S. Quinn, David Pearson, Dexiu Bu, Pedro Milanez-Almeida, Jennifer Mataraza, Omar Nadeem, Jessica Liegel, Anita D’Souza, Allison Charles, Marc Credi, Jerome Ritz, Andrzej J. Jakubowiak, Serena De Vita, Nikhil C. Munshi

Open source

DOI: 10.1126/scitranslmed.adx1799
Published: 2026-05-27
Container: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1126/scitranslmed.adx1799,
  title = {Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma},
  author = {Adam S. Sperling and Benjamin A. Derman and Sarah Nikiforow and Alejandro Alonso and Shuntaro Ikegawa and Nina Orwitz and David S. Quinn and David Pearson and Dexiu Bu and Pedro Milanez-Almeida and Jennifer Mataraza and Omar Nadeem and Jessica Liegel and Anita D’Souza and Allison Charles and Marc Credi and Jerome Ritz and Andrzej J. Jakubowiak and Serena De Vita and Nikhil C. Munshi},
  year = {2026},
  journal = {Science Translational Medicine},
  doi = {10.1126/scitranslmed.adx1799},
  url = {https://doi.org/10.1126/scitranslmed.adx1799}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
AU  - Adam S. Sperling
AU  - Benjamin A. Derman
AU  - Sarah Nikiforow
AU  - Alejandro Alonso
AU  - Shuntaro Ikegawa
AU  - Nina Orwitz
AU  - David S. Quinn
AU  - David Pearson
AU  - Dexiu Bu
AU  - Pedro Milanez-Almeida
AU  - Jennifer Mataraza
AU  - Omar Nadeem
AU  - Jessica Liegel
AU  - Anita D’Souza
AU  - Allison Charles
AU  - Marc Credi
AU  - Jerome Ritz
AU  - Andrzej J. Jakubowiak
AU  - Serena De Vita
AU  - Nikhil C. Munshi
PY  - 2026
JO  - Science Translational Medicine
DO  - 10.1126/scitranslmed.adx1799
UR  - https://doi.org/10.1126/scitranslmed.adx1799
ER  -

APA

Sperling, A. S., Derman, B. A., Nikiforow, S., Alonso, A., Ikegawa, S., Orwitz, N., Quinn, D. S., Pearson, D., Bu, D., Milanez-Almeida, P., Mataraza, J., Nadeem, O., Liegel, J., D’Souza, A., Charles, A., Credi, M., Ritz, J., Jakubowiak, A. J., Vita, S. D., & Munshi, N. C. (2026). Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adx1799

Source records

crossref · retrieved 2026-09-27T17:22:57.719Z